• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过可控孔隙率不对称膜胶囊实现氟比洛芬的渗透给药。

Osmotic delivery of flurbiprofen through controlled porosity asymmetric membrane capsule.

作者信息

Choudhury Pratim K, Chauhan Chetan S, Ranawat Mahendra S

机构信息

Department of Pharmacy, Fiji School of Medicine, Suva, Fiji Islands.

出版信息

Drug Dev Ind Pharm. 2007 Oct;33(10):1135-41. doi: 10.1080/03639040701386087.

DOI:10.1080/03639040701386087
PMID:17963115
Abstract

The release of poorly water-soluble drug, flurbiprofen, through asymmetric membrane capsule of cellulose acetate containing different pore forming agents like glycerol, polyethylene glycol 400, and dibutyl phthalate, in presence of sodium lauryl sulfate was investigated. The asymmetric membrane was fabricated in the shape of capsule body and cap by phase inversion technique. The type of pore forming agent incorporated had a marked influence on the porosity of the asymmetric membrane. However flurbiprofen due to its poor solubility was unable to create enough osmotic pressure and hence less than 10% of drug was released from all the systems with out SLS. However when the study was conducted with SLS, a maximum release of 72% was observed from the capsule with 70% glycerol. The release rates were found to increase with the increase in the concentration of pore forming agent and the amount of SLS encapsulated.

摘要

研究了在十二烷基硫酸钠存在的情况下,难溶性药物氟比洛芬通过含有不同致孔剂(如甘油、聚乙二醇400和邻苯二甲酸二丁酯)的醋酸纤维素不对称膜胶囊的释放情况。通过相转化技术将不对称膜制成胶囊体和帽的形状。所加入的致孔剂类型对不对称膜的孔隙率有显著影响。然而,由于氟比洛芬溶解度差,无法产生足够的渗透压,因此在没有十二烷基硫酸钠的情况下,所有体系中药物释放量均低于10%。然而,当在十二烷基硫酸钠存在下进行研究时,观察到含有70%甘油的胶囊中药物最大释放量为72%。发现释放速率随着致孔剂浓度和包封的十二烷基硫酸钠量的增加而增加。

相似文献

1
Osmotic delivery of flurbiprofen through controlled porosity asymmetric membrane capsule.通过可控孔隙率不对称膜胶囊实现氟比洛芬的渗透给药。
Drug Dev Ind Pharm. 2007 Oct;33(10):1135-41. doi: 10.1080/03639040701386087.
2
Controlled porosity osmotic pump for the delivery of flurbiprofen.用于递送氟比洛芬的控孔渗透泵
Curr Drug Deliv. 2006 Apr;3(2):193-8. doi: 10.2174/156720106776359203.
3
Asymmetric membrane capsule for osmotic delivery of flurbiprofen.用于氟比洛芬渗透给药的不对称膜胶囊
Acta Pharm. 2007 Sep;57(3):343-50. doi: 10.2478/v10007-007-0027-3.
4
Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.用于通过渗透作用递送难溶性药物的不对称膜胶囊。
Int J Pharm. 2005 Jun 13;297(1-2):89-97. doi: 10.1016/j.ijpharm.2005.03.026.
5
Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice.具有不对称膜结构的渗透型壳聚糖胶囊的新型设计,用于原位形成给药孔。
Int J Pharm. 2006 Aug 17;319(1-2):71-81. doi: 10.1016/j.ijpharm.2006.03.041. Epub 2006 Apr 7.
6
Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.氟比洛芬通过原位形成的不对称膜胶囊的渗透调节流动。
Curr Drug Deliv. 2008 Apr;5(2):127-32. doi: 10.2174/156720108783954824.
7
Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.关于具有原位形成给药孔的不对称膜包衣胶囊药物释放机制的研究。
J Control Release. 2003 Apr 14;89(1):57-69. doi: 10.1016/s0168-3659(03)00091-9.
8
In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug.用于难溶性药物渗透释放的原位形成不对称膜胶囊。
PDA J Pharm Sci Technol. 2007 Jan-Feb;61(1):24-36.
9
Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug.湿法诱导相转变药物递送系统:一种实现难溶性药物渗透、控释和A级体内体外相关性的手段。
Drug Dev Ind Pharm. 2008 Jul;34(7):735-43. doi: 10.1080/03639040801911032.
10
A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.一种新型非对称膜渗透泵胶囊,具有原位形成的释药孔,用于格列齐特固体分散体系统的控释。
Int J Pharm. 2016 Jun 15;506(1-2):340-50. doi: 10.1016/j.ijpharm.2016.04.061. Epub 2016 Apr 27.